Recombinant factor IX for clinical and research use

Paul E. Monahan, Jorge Di Paola

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations

Abstract

The last significant advance in the therapy of hemophilia B was the introduction of recombinant factor IX (FIX), ensuring an advanced level of safety from potential infectious contaminants of plasma-derived clotting factors. Since that time, recombinant DNA techniques have been applied in research to elucidate the role of FIX and its functional domains within coagulation. At the same time, recombinant DNA technology has been applied to engineer an expanding spectrum of novel FIX therapies that are now being translating into clinical trials. The experience with the existing recombinant FIX product is reviewed with a focus on the novel products and the potential to improve the quality of life for individuals with hemophilia B.

Original languageEnglish
Pages (from-to)498-509
Number of pages12
JournalSeminars in Thrombosis and Hemostasis
Volume36
Issue number5
DOIs
StatePublished - 2010

Keywords

  • Factor IX
  • hemophilia B
  • hemostasis
  • recombinant

Fingerprint

Dive into the research topics of 'Recombinant factor IX for clinical and research use'. Together they form a unique fingerprint.

Cite this